01.04.2020 - 31.07.2020

An open labeled randomized controlled pragmatic trial to evaluate the efficacy and safety of Montelukast as add on treatment to the novel coronavirus pneumonia (COVID-19)

Ref
no ref

Financing Instituitions
Apoio Research 4 Covid-19 - FCT

Participating Institutions
Centro Hospitalar São João

Summary

 

Montelukast may be an adjuvant drug in HCoV-19 treatment, either by improving lung injury, or by acting on HCoV-19 3CLpro. We aim to evaluate efficacy and safety of montelukast as an adjuvant on HCoV-19 by conducting a randomized, controlled, parallel, open-label, pragmatic trial in 160 hospitalized adult patients with the novel coronavirus pneumonia. Endpoints will include time to clinical improvement, hospitalization data. Safety outcomes will consider adverse events.

 

Investigador Responsável: André Moreira, PhD

Orçamento: 30.000,00 €